Analysis Laboratorios Farmaceuticos Rovi, S.A. (0ILL)
5/28/2024
Analysis of Laboratorios Farmaceuticos Rovi, S.A. (0ILL)
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that seems to be performing well based on the provided data. Here are some key points from the data:1. **Price Movement**: The closing prices have been increasing over the past few days, indicating a positive trend in the stock price.
2. **Technical Indicators**:
- **RSI Indicator**: The Relative Strength Index (RSI) values are generally above 50, indicating a bullish momentum in the stock.
- **MACD Indicator**: The Moving Average Convergence Divergence (MACD) values are positive, suggesting a bullish trend.
- **Moving Averages**: The stock price is above the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), which are all positive signs.
3. **Overall Analysis**: Laboratorios Farmaceuticos Rovi, S.A. appears to be in an uptrend based on the price movement and technical indicators. Investors may view this as a positive sign for the company's stock.
Please note that this analysis is based on historical data and trends can change quickly in the stock market. It's always recommended to conduct thorough research and consider various factors before making investment decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company over the specified periods, with the highest growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1% per annum.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11% per annum.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the historical average. However, the company is still projected to experience solid growth both in the short and long term according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the majority clustering around the median and average values. The current price is below both the median and average forecast, indicating that there may be potential upside according to the analysts' predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.44.
Moving on to stock statistics, the company has a short ratio of 1.66, with 94.31 million shares shorted out of 15.31 billion float shares. The average trading volume over 10 days is 52.90 million shares and over 90 days is 62.82 million shares. The company has a market capitalization of $2.91 trillion.
Valuation metrics show a PEG ratio of 26.21, forward PE ratio of 26.21, and trailing PE ratio of 29.43. The enterprise value is $2.95 trillion, with a price to book ratio of 39.18 and price to sales ratio of 7.62.
In terms of stock price summary, the company has a beta of 1.26, with a 50-day moving average of $173.69 and a 200-day moving average of $180.79. The stock's 52-week low is $164.08, high is $199.62, and the change over the 52 weeks is 8.25%.
Lastly, in dividends and splits, the company has a payout ratio of 14.93% and pays a forward annual dividend rate of $1, with a yield of 0.53%. The 5-year average dividend yield is 0.73%. The last split date was on August 31, 2020, with a 4-for-1 split. The ex-dividend date is May 10, 2024, and the dividend date is May 16, 2024.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a decrease in revenue from FY 2022 to FY 2023.
- Prior to the decrease, there was a consistent growth in revenue from FY 2020 to FY 2022.
- The revenue in FY 2023 is still higher than that in FY 2021 and FY 2020.
These trends indicate fluctuations in the company's revenue performance over the past four years, with a notable decrease in the most recent fiscal year.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been increasing over the years, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant fluctuations, especially in common stock repurchases and long-term debt issuuance.
5. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
6. The end cash position has been fluctuating, but generally, the company has maintained a healthy cash balance.
7. Stock-based compensation has been a significant factor in the company's financial activities.
8. The company has been paying dividends consistently, with varying amounts each year.
9. The company has engaged in acquisitions and divestitures, impacting the investing cash flow.
10. Overall, the company's cash flow statement reflects a mix of stability and variability in its financial activities over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, compared to $1.26 a year ago. The range of estimates is between $1.27 and $1.36, based on 26 analysts' forecasts.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, lower than the $1.46 reported a year ago. The estimates range from $1.44 to $1.63, with 25 analysts providing forecasts.
3. Looking at the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, up from $6.13 in the previous year. The low estimate is $6.43, while the high estimate is $6.92, based on projections from 39 analysts.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, compared to $6.59 in the previous year. The EPS estimates range from $6.40 to $7.90, with 39 analysts contributing to the forecasts.
Overall, the analysts are generally optimistic about the company's future earnings per share, with expected growth in both the short term and the long term.
MACD of 0ILL
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
